electroCore (NASDAQ:ECOR - Free Report) had its price target hoisted by HC Wainwright from $22.00 to $25.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.
electroCore Trading Up 11.1 %
ECOR stock traded up $1.54 during trading on Wednesday, reaching $15.47. 532,106 shares of the stock were exchanged, compared to its average volume of 35,761. electroCore has a twelve month low of $5.25 and a twelve month high of $17.84. The company has a market capitalization of $101.41 million, a P/E ratio of -8.45 and a beta of 0.57. The stock has a 50 day simple moving average of $11.38 and a 200-day simple moving average of $8.07.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in electroCore by 10.3% during the third quarter. Geode Capital Management LLC now owns 63,485 shares of the company's stock worth $458,000 after buying an additional 5,951 shares in the last quarter. HighTower Advisors LLC bought a new position in shares of electroCore during the 3rd quarter worth about $255,000. International Assets Investment Management LLC boosted its position in shares of electroCore by 689.1% during the 3rd quarter. International Assets Investment Management LLC now owns 535,146 shares of the company's stock valued at $3,864,000 after acquiring an additional 467,326 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in electroCore by 3.4% in the second quarter. Renaissance Technologies LLC now owns 68,786 shares of the company's stock valued at $442,000 after acquiring an additional 2,270 shares during the period. 26.74% of the stock is currently owned by institutional investors and hedge funds.
electroCore Company Profile
(
Get Free Report)
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Featured Articles
Before you consider electroCore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.
While electroCore currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
